Abstract 3069
Background
Skeletal muscle loss is a central component of cancer cachexia syndrome and is a poor prognostic factor in patients with cancer. We investigated prevalence of sarcopenia and the feasibility of exercise intervention in patients with newly diagnosed advanced solid cancer.
Methods
Between July 2017 and February 2018, consecutive patients with newly diagnosed advanced solid cancer were enrolled to our prospective cohort. Sarcopenia was defined as the third lumbar vertebra(L3) muscle index of less than 55 cm2/m2 for men and of less than 39 cm2/m2 for women. Patients were recruited to participate in a 12-week, combined resistance and aerobic exercise program consisted of supervised, hospital-based (2x/week) and home-based training (3x/week), during the first-line palliative chemotherapy. The primary endpoint were feasibility and safety of the exercise intervention. Pre- and post- exercise intervention skeletal muscle mass by bioelectrical impedance analysis(BIA) and patients’ quality of life questionnaires were measured and compared.
Results
Among 76 patients enrolled in the prospective cohort, sarcopenia was present in 58 (76.3%) patients (94.3% in men, 34.8% in women). Nineteen patients was enrolled in the exercise program, however 5 patients withdrew consent before commencement. Reasons for withdrawal were health concern (n = 2), distance to the hospital (n = 1) and unspecified (n = 2). The completion rate of the 12-week exercise program was 78.6% (11/14). Disease progression (n = 2) was the main reason for early discontinuation. The adherence rate of the supervised exercise session was 78.1% (207/265) and there was no adverse event associated with the exercise training. Among participants in the exercise program, there was no significant change in skeletal muscle index from baseline to post-intervention (mean, 9.4±1.3kg/m2 vs 9.4±1.2kg/m2, p = 0.982). FACIT-fatigue scale was non-significantly improved after the exercise intervention (mean, 35.2±10.4 vs 38.2±9.8, p = 0.635).
Conclusions
Exercise interventions appear to be feasible and safe in patients with advanced solid cancer and might have a role of preventing skeletal muscle loss without fatigue exacerbation during palliative chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Gachon University Gil Medical Center.
Funding
National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (grant no. HA17C0045).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract